Translational Analysis

Understand why treatments work and why they don't

We help translational teams investigate the biological mechanisms associated with response and resistance, using integrated clinical and molecular data to generate reproducible, decision-ready evidence.

Strengthen biomarker strategy. Refine patient selection. Support program decisions.

Secure TRE Reproducible Workflows Built for Traceability
The challenge

The Translational Challenge

Understanding treatment response requires more than identifying signals. It requires explaining the biology behind them. Molecular and clinical data are often disconnected, making it difficult to link biomarkers to mechanism, evaluate findings, and generate evidence that can guide program decisions.

Biomarkers

Which biomarkers truly predict response and why?

We connect molecular signals to biological pathways and clinical outcomes to distinguish meaningful biomarkers from noise.

Mechanism

How do responders differ from non-responders at a biological level?

We integrate multi-modal datasets to investigate the mechanisms associated with response and resistance.

Evidence

What biological mechanisms explain treatment response?

We generate mechanistic insights that support biomarker strategy, patient selection, and program direction.

Deliverables

What We Deliver

We deliver mechanistic and biomarker evidence that helps teams understand treatment response and make better-informed program decisions.

Sonrai Discovery: Volcano plot
Volcano plot of differential expression analysis
Example output: differential expression analysis, responders vs non-responders

What you receive

Candidate biomarker evaluation

Evaluate candidate biomarkers linked to response and resistance across datasets and modalities.

Responder vs non-responder biology

Evaluate biological differences associated with treatment response using integrated multi-modal data.

Translational evidence reports

A report that connects findings to your question, with annotated figures, candidate priorities, analytical limitations and recommended next analyzes.

Mechanism of action insights

Investigate the biological pathways and mechanisms associated with treatment response.

Associations with treatment response do not, by themselves, establish predictive performance or a causal mechanism.

Data types

Built on Integrated Multi-Modal Data

Understanding treatment response requires connecting signals across datasets. Sonrai integrates clinical and molecular datasets within a structured analytical environment, so each modality contributes to a coherent, reproducible picture of treatment response.

Transcriptomic
RNA-seq and transcriptomics

Evaluate gene expression patterns linked to response and resistance.

Genomic
Genomics and variant data

Explore genetic variants associated with treatment outcomes.

Single-cell
Single-cell sequencing

Explore cellular-level differences between responder populations.

Clinical
Clinical trial datasets

Link molecular signals to clinical outcomes and endpoints.

Immune
Flow cytometry and immune profiling

Characterize immune response dynamics associated with treatment.

Imaging
Imaging and histopathology

Assess spatial and phenotypic signals linked to disease biology.

Proteomic
Proteomics and cytokine data

Capture protein-level signals associated with treatment response.

Our process

How Teams Work With Sonrai

We work with your team to define the right biological question, integrate multi-modal data, and deliver reproducible evidence that explains treatment response and supports program decisions.

01

Define the scientific question

Align on mechanism, biomarker hypotheses, and the translational context driving the analysis.

Mechanism scoping Biomarker hypotheses Dataset review
02

Integrate and analyze multi-modal data

Combine clinical and molecular datasets to evaluate the biological signals associated with response and resistance.

Multi-modal integration Signal evaluation Secure TRE
03

Deliver decision-ready evidence

Provide clear, reproducible outputs that support biomarker strategy, patient selection, and program direction.

Biomarker strategy Translational report Decision-ready
Sonrai Discovery: Expression heatmap
Gene expression heatmap of responder vs non-responder analysis
Example output: gene expression heatmap, responder vs non-responder cohort analysis

Explore methods, traceability and handover

Get started

Ready to explore your dataset?

If you're investigating treatment response or predictive biomarkers, Sonrai can help integrate and analyze your molecular, imaging, and clinical datasets to generate clear, reproducible translational evidence.

Talk to our team

What to expect

An initial conversation

We'll discuss your program, your datasets, and the biological question you need to answer.

A tailored analytical approach

We'll outline how we'd integrate your data to evaluate the biological signals associated with treatment response.

Decision-ready translational evidence

Clear, reproducible outputs your team can use to support biomarker strategy, patient selection, and program direction.

Common Questions

Questions about translational analysis and biomarker discovery

Questions from translational teams, biomarker leads and bioinformaticians about integrating multi-modal data, evaluating biomarker findings, and generating evidence that supports program decisions.

Can Sonrai work with RNA-seq, proteomics, imaging and clinical trial data we already generate?

Yes. Sonrai integrates transcriptomics, genomics, proteomics, single-cell sequencing, flow cytometry, whole slide imaging, and clinical trial datasets within a single governed analytical environment. If you are already generating these data types, Sonrai can connect them without requiring you to change how data is collected or stored. For a full breakdown of supported modalities, see the Sonrai data modalities page.

How can we generate stronger evidence for biomarker-driven program decisions?

Sonrai generates decision-ready evidence by integrating molecular and clinical datasets, running reproducible analyzes, and delivering outputs structured around a specific biological question, such as whether a biomarker predicts response, how responders differ from non-responders, or what mechanisms are driving resistance. Every output is traceable from raw data to finding. Examples include an illustrative multi-omic workflow built on simulated trial data, and bench-to-bedside immunotherapy development where preclinical and clinical data were integrated to support translational strategy.

What is the best way to integrate RNA-seq, proteomics, pathology imaging and clinical outcomes for biomarker discovery?

One effective approach is to integrate these datasets within a single governed analytical environment where cross-modality analyzes run on consistent, versioned data rather than manually stitched outputs. Sonrai connects transcriptomic, proteomic, imaging, and clinical trial data in this way, allowing differential expression analysis, multi-omics factor analysis (MOFA+), survival analysis, and patient stratification to run across modalities in a single workflow. This produces findings where molecular signals are directly connected to clinical outcomes rather than analyzed in isolation.

How do I identify predictive biomarkers that distinguish responders from non-responders?

Sonrai integrates your molecular and clinical datasets and runs comparative analyzes across defined responder and non-responder cohorts. Differential expression analysis identifies gene expression patterns linked to response. Multi-modal analyzes connect those signals to protein-level, imaging, and clinical endpoint data to build a biologically grounded picture of what distinguishes the two groups. Outputs include prioritized biomarker candidates, volcano plots, expression heatmaps, and translational evidence reports connecting molecular findings to clinical outcomes.

How do I know if a biomarker is biologically meaningful rather than a statistical artifact?

Statistical significance alone is not sufficient evidence that a biomarker is biologically meaningful. Sonrai addresses this by evaluating biomarker candidates across multiple modalities. A signal that appears in RNA-seq data and is corroborated by protein-level and imaging data is stronger evidence than one found in a single dataset. Internal trial cohort findings can also be assessed against public datasets within the same governed environment. This multi-modal, cross-dataset approach is designed to produce evidence that gives program teams a stronger basis for decisions than signals that fail to replicate.

How can I evaluate a predictive biomarker signature using both internal and public datasets?

Sonrai supports integration of internal proprietary datasets alongside public data sources within the same governed environment. Biomarker candidates identified in your trial cohort can be assessed against external datasets, strengthening the evidence base before committing to a stratification strategy. All cross-dataset analyzes run within a secure Trusted Research Environment with data provenance recorded, so you retain control over how your data is used and can show how findings were generated.

Can I continue using Nextflow, nf-core and my existing analytical workflows?

Yes. nf-core pipelines can be run on demand within the Sonrai environment. Teams are not locked into a proprietary workflow or a fixed set of methods. Bioinformaticians can work in code-based environments using existing tools and pipelines, while research scientists can use no-code applications on the same underlying data within the same governed instance. You bring your existing analytical approach into a governed, reproducible infrastructure rather than replacing it.

Should we build our own bioinformatics platform on AWS or use an existing solution?

Building on AWS gives you flexibility but requires significant ongoing investment in infrastructure engineering, pipeline maintenance, security compliance, and data governance, before a single analysis runs. Sonrai provides a governed, reproducible research environment with analytical pipelines, data integration tooling, and collaborative access already in place. Teams can avoid much of the build time, maintenance overhead, and reproducibility risk that comes with custom infrastructure. The core question is whether infrastructure engineering is the best use of your team's time relative to the science itself.

How much internal resource does a team need to commit to get value from a translational analysis engagement?

Sonrai works as an extension of your team rather than a service that requires significant internal coordination. The engagement begins with a focused scientific conversation to align on the biological question, the available datasets, and what a useful output looks like. From there, Sonrai manages data integration, analytical workflows, and reproducible outputs. Your team's primary input is scientific: defining the hypothesis, reviewing findings, and applying the evidence to program decisions. Sonrai runs the analyzes and manages the infrastructure, so internal bioinformatics resource is not needed for those tasks.

How quickly can a translational team go from raw multi-modal data to candidate biomarker findings?

Timeline depends on dataset complexity, the biological question, and data readiness. The process follows three stages: defining the scientific question and reviewing available datasets; integrating and analysing multi-modal data within a secure environment; and delivering reproducible outputs. Because Sonrai runs analysis within a governed infrastructure with versioned datasets and pre-built analytical workflows, teams avoid the setup time associated with building analytical environments from scratch. Talk to our team to get a realistic view of what is achievable for your specific program and dataset.